Jane Lebkowski, Asterias Biotherapeutics‘ VP of R&D, spoke to CIRM’s governing Board about the company’s CIRM-funded clinical trial for spinal cord injury. Richard Lajara, the fourth participant in a previous trial, gives a patient’s perspective.
Related Links:
